ADICON HOLDINGS cash and new share strategic acquisition involves an investment of 230 million RMB

阿斯達克財經網
2025.05.06 14:42

艾迪康控股 (09860.HK) 公佈一項戰略投資，向獨立第三方收購元德維康 (從事於血液診斷試劑的研發及生產) 全部股權，代價 1.79 億人民幣 (相當於 1.91 億港元)，將透過發行最多 2,902.57 萬股代價股支付，發行價 6.58 元，較上交易日 (6 日) 收報折讓 12.15%。

同時，集團內地 ICL(獨立醫學實驗室) 業務附屬杭州艾迪康向獨立第三方收購元德友勤 (專門從事醫學檢驗服務，擁有血液檢測專業知識) 全部股權，現金代價 5,000 萬人民幣。

Source: 阿斯達克財經網 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.